Introduction
In 1977, Andreas Gruntzig performed the first human balloon angioplasty and ushered in the era of percutaneous treatment for coronary artery disease. Initial enthusiasm was tampered down by reports of acute vessel occlusion due to dissections 1 and late constrictive remodeling. Next large leap was the introduction of bare metal stents. The BENESTENT trial 2 reported reduced vessel restenosis (22% vs. 32%, P = 0.02) and the need for repeat coronary angioplasty (RR, 0.58; P = 0.005) in BMS treated patients. The rate of sub-acute vessel occlusion decreased to 1.5%; reducing the need for emergency bypass surgery. In 1996 Schömig et al. 3 introduced dual anti-platelet instead of anticoagulant therapy, resulting in 82% lower risk of MI and 78% reduction in need for repeat interventions (RR 0.25(0.06-0.77).
In 2001 Surreys et al. 4 reported the first use of Drug Eluting Stents in 45 patients, who were treated with Sirolimus eluting Bx VELOCITY stents with negligible neo-intimal hyperplasia at oneyear follow-up. The RAVEL trial 5 reported lower mean late luminal loss (À0.01 mm vs. 0.80 mm, P < 0.001) and no recurrent revascularization attempts (vs. 26% in control). However, reports on late stent thrombosis surfaced, 6 which increased to 3.5% at 4 years. 7 
The promise of bioresorbable scaffolds
Initially, Tamai et al. 9 examined the feasibility of a bio-absorbable poly-L-lactic acid (PLLA) Igaki-Tamai stents (Igakl Medical, Kyoto, Japan) with a thickness of 0.17 mm and a zigzag helical coil pattern (not drug eluted). They reported 18% repeat revascularization at 4 years 10 and 28% target vessel revascularization at 10 years. One case of definite stent thrombosis was reported. 26, 29 Di Mario et al. 11 used magnesium stents in de-novo coronary lesions, with modest results (1-year Target Lesion Revascularization (TLR) rate 45%). The Bioresorbable Vascular Scaffold (BVS) (Abbott Vascular, California) consists of processed Poly-L-Lactic acid (PLLA) backbone covered with amorphous Everolimus/PLA matrix coating for controlled drug release. The use of polylactic acid is widespread in clinical practice, ranging from absorbable sutures to orthopedic screws and dermatology fillers. Safety of PLLA is supported by the benign vascular response to its use in Angioseal closure devices. PDLLA (poly(D,L-lactide), the polymer used for controlled release of Everolimus, has also been used previously.
14 Everolimus (Novartis, Switzerland) is a semi-synthetic macrolide immunosuppressant which blocks cell proliferation by arresting cell division in G1-S phase. BVS contains 8.2 mcg/mm of Everolimus, 80% of which is released within 30 days; similar to Xience V stent. Safety and efficacy of Everolimus eluting stents were attested in SPIRIT and FUTURE trials. [14] [15] [16] The BVS stent strives to perform comparably to others: its crossing profile is comparable to that of BX Velocity stent (1.4 mm). At room temperature, its radial strength is similar to MULTILINK stent. 12 Its balloon delivery system is the same as for MULTI LINK, VISION and XIENCE V stents. BVS also shows higher conformability to vessel structure. 31 Its initial version (Revision 1.0) had to be stored at low temperatures in order to avoid device instability and cracks upon deployment. The second generation (Revision 1.1) can be stored at room temperature. 24 Its previous polymer treatment and scaffold design were replaced with in-phase zigzag hoops linked by bridges, allowing for more uniform strut distribution, higher radial support, less vessel recoil and uniform drug distribution. 30 The BVS is composed of repeating units of PLLA/PDLLA. After implantation, bonds between repeating units get hydrolyzed producing lactic acid, which is metabolized via Krebs cycle and residual small particles (<2 mm) are phagocytosed by macrophages.
Chemically, scaffold resorption takes place in three phases; initially water starts hydrolysis of ester bonds, resulting in decline of stent's molecular weight. In the second stage there is scission of chains linking regions, causing decline in the radial strength. At third stage, remaining short polymer chains diffuse out of the device to get reabsorbed into blood.
Degradation of scaffold governs mechanical performance, which divides into three phases: during initial ''revascularization phase" it acts like mainstream drug eluting stents (comparable deliverability, minimal acute recoil and high radial strength). At the restoration phase there is hydrolysis of amorphous regions and connecting points, causing a decline in radial strength. In studied cases it took three months after implantation for the process to start. During the last ''resorption phase" the BVS becomes discontinuous and ceases to act as a scaffold while hydrolysis continues and generates L-and D-lactate into the body, 22 meanwhile the stent strut sites become occupied with proteoglycan material and strut outline becomes surrounded by calcification. 23 In most cases this process may take up to 24 months. In animal studies there were complete luminal endothelialization and minimal Inflammatory response, which is comparable to earlier reports with Cypher stents (J&J, Miami,Fl). 12 At 6 months these arteries were still splinted; and at 12 months the vessel became capable of autovasomotion. 12, 24 In 2006, Ormiston et al. reported the first BVS in man implantation. 13 In 2008 the ABBSORB FIRST 17 reported 94% device success rate in 30 patients with single de-novo coronary lesions who underwent BVS implantation (Table 1) . At one year, only one patient needed target vessel revascularization. IVUS showed post-procedural incomplete strut apposition in 6 patients and no late stent thrombosis was reported. At 6 months, the OCT substudy showed 99% of struts where covered with tissue. At 2 years there was 34.5% decrease in strut thickness. 24 These patients showed higher acute stent recoil than EES stents (percent recoil 6.9% % vs. 4.3% historical data from SPIRIT FIRST and SPIRIT II; P = 0.25). 18 IVUS data also noted significant late stent recoil (7.6% 19 vs. 0.03% Xience V. 15, 17 This translated into 0.44 mmlate lumen loss at six months. Partly, this is due to neointimal hyperplasia and the rest is due to reduction inside stent area. Hyperplasia was comparable to that observed in SPIRIT FIRST with Xience and was better than BMS. 15 Reduction in inside stent area was due to acute stent recoil, non-uniform vessel wall support and loss of radial strength through scaffold resorption. In-stent restenosis rate was 11.5%, which did not necessitate re-intervention. From 6 months to 2 years there was a reduction in plaque area, 24 while the vessel size remained same, leading to gain in lumen area, with no scaffold mal-apposition noted. 25 
Evidence from real life registries
The large GHOST-EU registry 34 34 
2015
Included 1189 patients who underwent percutaneous coronary intervention with one or more BVS at 10 European centers Technical success was achieved in 99.7% of cases TLF was 2.2% at 30 days and 4.4% at six months At 6 months rate of cardiac death was 1.0%, target vessel myocardial infarction was 2.0%, TLR was 2.5%, and target vessel revascularization was 4.0% Diabetes mellitus was the only independent predictor of TLF (hazard ratio 2.41, 95% confidence interval: 1.28-4.53; p = 0.006) Incidence of definite/probable scaffold thrombosis was 1.5% at 30 days and 2.1% at six months Naganuma et al. 43 
2017
1189 patients underwent PCI with BVS at 10 European centers (GHOST EU registry). Of these, 289 consecutive patients (302 bifurcation lesions) were treated with either single-stenting (n = 260) or double-stenting (n = 42)
At 360 days rate of target lesion failure was 6.4% rate of scaffold thrombosis was 2.5% Independent predictors for TLF: ACS and diabetes mellitus (HR 4.67; 95% CI: 1.78-12.3; P = 0.002 and HR 3.37; 95% CI: 1.38-8.26; P = 0.008, respectively) MACE: Major adverse cardiac events. BRS: Bioresorbable Scaffold. EES: Everolimus-eluting stents. BES: Biolimus-eluting stents. TLF: Target lesion failure. TLR: Target lesion revascularization.
1.33;1.04-1.70, p = 0.024). BVS overlap did not increase MACE (HR 1.05,0.48-2.20; P = 0.904), 45 as confirmed by another group. 46 Another analysis of the GHOST-EU registry looked at BVS use in diffusely diseased vessels. 38 Patients were divided into 3 groups In another registry, 302 bifurcation lesions were treated using BVS (provisional single-stenting 86%; elective double-stenting 14%). True bifurcation (Medina 1,1,1/1,0,1/0,1,1) were observed in 45%. Pre-dilation and post-dilation of the main branch were performed in 96% and 61%. Final kissing inflation with small protrusion of a side branch balloon into main branch was performed in 19%. At 356 days follow up rates of target lesion failure and scaffold thrombosis were high at 6.4% and 2.5%. Independent predictors for TLF were ACS presentation and diabetes (HR 4.67; 1.78-12.3; P = 0.002 and HR 3.37; 95%:1.38-8.26; P = 0.008, respectively). Majority of patients with scaffold thrombosis occurred within 35 days from index PCI (75%) and lacked use of intravascular imaging. 40, 43 Acute coronary syndrome presentation once again showed poorer outcomes 45 (MACE 9.3% vs. 4.7%, p < 0.001; TLR 6.1% vs.
1.9%, p < 0.001) with increased stent thrombosis (BVS 2.8% vs. 0.9% EES group, p = 0.01). Here post-dilatation resulted in lower MACE (BVS with post-dilatation 6.0% vs. 12.6% BVS without postdilatation vs. 4.7% EES group, p < 0.001). Post dilatation did not alter the rate of stent thrombosis (post-dilatation: 2.6% vs. no post-dilatation: 3.2% vs. 0.9%: EES patients, p = 0.045). 45 Review of real world registries shows an increasing trend for post-dilation. We note a change from 52.3% rate in GHOST EU, 36 to 68% in GABI-R, 52 72% in FRANCE ABSORB, 53 to 96.8% in IT-DISAPPEAR; 54, 55 which also enrolled the most complicated patients (59%, diabetics 23.7%, bifurcation lesions 22.3%). This is accompanied by a concomitant decline in BVS thrombosis, initially observed at 3.4% in GHOST EU (least post-dilatation rate) to 0.6% in IT-DISAPPEAR. Recent emphasis on implantation technique formulated the nomenclature of four P's: Prepare the lesion with non-compliant balloon, Proper sizing with use of intracoronary nitroglycerin and imaging as necessary; Pay attention to expansion limits; staying within nominal limits of 0.5 mm and expanding the scaffold at 2 mm every five seconds while implanting, then staying 30 s when fully expanded before deflating. Finally Post-dilating with a noncompliant balloon at high pressure aiming at <10% residual stenosis after implantation. By using this protocol and avoiding small vessels with lumen diameters <2.5; BVS thrombosis rates can be reduced by 70%. 56 In order to clarify the issues concerning BVS use for clinicians, the FDA issued a ''Dear Doctor" letter noting it that the higher risk of stent-related thrombosis and other major cardiac events among patients who got Absorb GT1 BVS is under investigation. It reminds operators using BVS to follow instructions in FDA labeling, avoiding its use in small vessels and to adhere to the label's recommended implantation technique.
In 14th September 2017, Abbott decided to voluntarily withdraw its product from market except for patients in the setting of a registry or study, citing low market penetration. Abbott promised to come back with a new improved scaffold of 92 mm thickness.
To summarize, despite having only a fraction of the tensile strength of metallic stents (30-45 compared to 820-1200 MPA); the BVS showed favorable 1 year results in large studies despite a possible small but statistically significant increased risk of periprocedural MI. Longer term follow up showed higher BVS late thrombosis rates and higher target lesion failure. This may be due to numerous factors. For example, 19% of patients in ABSORB III 60 were treated for vessels which were smaller than the size advised by the FDA. Clinicians tend to use visual assessment to in estimating vessel size rather than quantitative analysis. This may result in underestimating vessel size. Moreover, techniques of implantation have been largely suboptimal (only 63% of BVS recipients had post-dilatation in ABSORB III 60 ). Diligent attention to choosing vessels of appropriate diameter and paying attention to technique of implantation, more frequent use of imaging for vessel sizing should result in improved outcomes. This needs to be shown in long-term follow up of Absorb III and IV studies which could then open the door for introduction of newer generation of scaffolds. Other scaffolds are also already in clinical use, 61, 62 though to a lesser extent and their long term clinical efficacy remains to be shown too.
